A vaccine developed by researchers at the U.S. National Institute of Health has been fast-tracked by regulators and its first human safety trial expected to begin in September.
A report from Washington on Friday stated that the vaccine was based on a chimpanzee adenovirus, a relative of cold viruses.
It said scientists were racing to begin the first human safety tests of two experimental Ebola vaccines, but it won’t be easy to prove that the shots and other potential treatments in the pipeline really work.
It said British drug maker GlaxoSmithKline was ushering the potential injection through the development process, after acquiring its original developer, vaccine specialist Okairos AG, for 325 million dollars on 2013.
It said studies showed the vaccine could protect monkeys from the virus.
There are no proven drugs or vaccines for Ebola, a disease so rare that it had been hard to attract investments in countermeasures.
Xinhua & NAN
ABUJA: Training Schedule for Basic Life Support BLS, Pediatric Advanced Life Support (PALS), Advanced Cardiovascular Life Support ACLS, First Aid, CPR, AED
PORTHARCOURT: Training Schedule for Basic Life Support BLS, Pediatric Advanced Life Support (PALS), Advanced Cardiovascular Life Support ACLS, First Aid, CPR, AED
LAGOS: Training Schedule for Basic Life Support BLS, Pediatric Advanced Life Support (PALS), Advanced Cardiovascular Life Support ACLS, First Aid, CPR, AED
STOP paying for airtime and electricity, Let your phone pay its bills with ScreenT